Suppression of oxidative stress and 5-lipoxygenase activation by edaravone improves depressive-like behavior after concussion

J Neurotrauma. 2014 Oct 15;31(20):1689-99. doi: 10.1089/neu.2014.3331. Epub 2014 Aug 21.

Abstract

Brain concussions are a serious public concern and are associated with neuropsychiatric disorders, such as depression. Patients with concussion who suffer from depression often experience distress. Nevertheless, few pre-clinical studies have examined concussion-induced depression, and there is little information regarding its pharmacological management. Edaravone, a free radical scavenger, can exert neuroprotective effects in several animal models of neurological disorders. However, the effectiveness of edaravone in animal models of concussion-induced depression remains unclear. In this study, we examined whether edaravone could prevent concussion-induced depression. Mice were subjected to a weight-drop injury and intravenously administered edaravone (3.0 mg/kg) or vehicle immediately after impact. Serial magnetic resonance imaging showed no abnormalities of the cerebrum on diffusion T1- and T2-weighted images. We found that edaravone suppressed concussion-induced depressive-like behavior in the forced swim test, which was accompanied by inhibition of increased hippocampal and cortical oxidative stress (OS) and suppression of 5-lipoxygenase (5-LOX) translocation to the nuclear envelope in hippocampal astrocytes. Hippocampal OS in concussed mice was also prevented by the nicotinamide adenine dinucleotide phosphate oxidase inhibitor, apocynin, and administration of BWB70C, a 5-LOX inhibitor, immediately and 24 h after injury prevented depressive-like behaviors in concussed mice. Further, antidepressant effects of edaravone were observed in mice receiving 1.0 or 3.0 mg/kg of edaravone immediately after impact, but not at a lower dose of 0.1 mg/kg. This antidepressant effect persisted up to 1 h after impact, whereas edaravone treatment at 3 h after impact had no effect on concussion-induced depressive-like behavior. These results suggest that edaravone protects against concussion-induced depression, and this protection is mediated by suppression of OS and 5-LOX translocation.

Keywords: 5-lipoxygenase; concussion; depression; edaravone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antipyrine / analogs & derivatives*
  • Antipyrine / pharmacology
  • Antipyrine / therapeutic use
  • Arachidonate 5-Lipoxygenase / metabolism*
  • Brain / pathology
  • Brain Chemistry / drug effects
  • Brain Concussion / complications*
  • Brain Concussion / pathology
  • Brain Concussion / psychology*
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / etiology
  • Depressive Disorder / psychology*
  • Dose-Response Relationship, Drug
  • Edaravone
  • Enzyme Activation / drug effects
  • Lipoxygenase Inhibitors / therapeutic use*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Oxidative Stress / drug effects*
  • Psychomotor Performance / drug effects
  • Swimming / psychology

Substances

  • Lipoxygenase Inhibitors
  • Neuroprotective Agents
  • Arachidonate 5-Lipoxygenase
  • Edaravone
  • Antipyrine